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Background: A randomized, unmasked, multicenter study was conducted to evaluate the rate of pruritus reduction
and improvement in clinical scoring by cyclosporine A (5 mg/kg orally, once daily for 28 days) either alone (n = 25
dogs) or with concurrent prednisolone (1 mg/kg once daily for 7 days, followed by alternate dosing for 14 days; n = 23
dogs) for the treatment of atopic dermatitis in dogs. Dogs were included in the study after exclusion of other causes of
pruritic dermatitis, and were assessed by dermatologists on days 0, 14 ± 1 and 28 ± 2. Assessments included: general
physical examination, CADESI-03 lesion scoring, overall clinical response, evaluation of adverse events (AEs), body
weight and clinical pathology (hematology, clinical chemistry and urinalysis). Owner assessments, including pruritus
(visual analogue scale, VAS) and overall assessment of response were conducted every 3–4 days, either during visits to
the clinic or at home. Owners reported AEs to the investigator throughout the study.
Results: By day 28 ± 2 both treatment groups resulted in a significant improvement of the atopic dermatitis. Both
investigators and owners agreed that concurrent therapy resulted in a quicker improvement of the dogs ‘overall’ skin
condition and of pruritus (significant reduction of pruritus by day 3–4, 72.8% improvement by day 14 ± 1), when
compared to cyclosporine A alone (significant reduction of pruritus by day 7–8, 24.7% improvement by day 14 ± 1).
CADESI-03 scores significantly improved in both groups by day 14 ± 1 onwards, and there were no significant
differences in the scores between treatment groups at any time points. A total of 56 AEs (cyclosporine A alone = 34;
concurrent therapy = 22) were reported in 33 dogs. No dogs died or stopped treatment due to an AE. The most
commonly reported AEs in the cyclosporine A group were associated with the digestive tract, whilst systemic disorders
were reported more frequently observed following concurrent therapy. Evaluation of body weight change and clinical
pathology indices showed no overall clinically significant abnormalities.
Conclusions: In dogs with atopic dermatitis, a short initiating course of prednisolone expedited the efficacy of
cyclosporine A in resolving pruritus and associated clinical signs. The observed adverse events were consistent with
those expected for the individual veterinary medicinal products.
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Atopic dermatitis, a common skin disease of dogs, is defined
as a genetically predisposed inflammatory and pruritic skin
disease with characteristic clinical features associated with
IgE antibodies, usually directed against environmental aller-
gens [1,2]. The chronic form of the disease is characterised
by pruritus with or without recurrent skin or ear infections.
Primary skin lesions usually consist of erythematous mac-
ules, patches and small papules. Most patients, however,
present with lesions that occur secondary to self-trauma, in-
cluding self-induced alopecia, lichenification and hyperpig-
mentation. In addition to measures such as allergen
avoidance and improved skin and coat hygiene, pharma-
cological agents are often necessary to manage the inten-
sity of pruritus, which has an impact on the perceived
quality of life of both owner and dog [3].
The 2010 practice guidelines issued by the International
Task Force on Canine Atopic Dermatitis (now the Inter-
national Committee on Allergic Diseases of Animals) con-
cluded that there is good evidence for the high efficacy of
both oral cyclosporine A and oral glucocorticoids such as
prednisolone, as a treatment for chronic atopic dermatitis
in dogs [4]. Both are equally effective treatments but
have different modes of action and clinical response
profiles [5]. Cyclosporine A, a cyclic oligopeptide macrolide,
blocks the activity of cytoplasmic calcineurin phosphatase
thereby specifically inhibiting cytokine induced activation of
cells that initiate the cutaneous immune response and medi-
ate allergic reactions. Glucocorticoids bind to the cytosolic
glucocorticoid receptor, thereby regulating cellular gene
expression and protein transcription, exerting a wide var-
iety of systemic effects including the anti-inflammatory ac-
tion which helps to reduce pruritus. Glucocorticoids, such
as prednisolone when dosed at 0.5 mg/kg twice daily, have
a rapid onset of clinical activity; cyclosporine A requires
approximately four weeks of therapy (5 mg/kg once daily)
for maximal clinical improvement, before the dose may
then be reduced [6]. Undesirable effects of chronic oral
glucocorticoid therapy (e.g. polyuria, polydipsia, polypha-
gia, predisposition to urinary tract and skin infections) are
common, but even short term use can have systemic con-
sequences such as urinary incontinence and lethargy [5,7].
Common adverse events after initiating cyclosporine A
therapy (e.g. vomiting, diarrhoea) generally improve spon-
taneously upon further administration [6]. For these rea-
sons, together with its more targeted action, cyclosporine
A is an excellent treatment option for life-long therapy of
chronic atopic dermatitis in dogs [6,8].
Prolonged administration of elevated doses of glucocor-
ticoids to dogs can result in immunosuppressive effects
(recently reviewed by Whitley NT and Day J [9]). Simi-
larly, administration of cyclosporine A at doses higher
than those recommended for the treatment of atopic
dermatitis have been used for the treatment of immune-mediated disease [10,11]. Therefore, the concurrent
long-term administration of oral cyclosporine A and
glucocorticoids is not recommended, as potential com-
bined immune suppression could result in a higher risk
for development of potentially severe opportunistic in-
fections of the skin or other organs. However, the ad-
ministration of a short course of oral glucocorticoids
during the first 2 weeks of cyclosporine A administra-
tion has been suggested as a therapeutic strategy to ac-
celerate the improvement of pruritic signs of atopic
dermatitis [4]. To the best of our knowledge, this treat-
ment regimen has not previously been assessed under
controlled conditions. Therefore, in this study both the
efficacy and safety of such a regimen were evaluated in
a multicenter clinical trial.
Methods
Study design
This was a randomized multicenter field study designed
to compare the safety and the rate of improvement of
pruritus reduction and other signs of atopic dermatitis
in dogs by cyclosporine A alone or with the concomitant
administration of prednisolone during the initiation of
cyclosporine A therapy. Neither investigators nor owners
were blinded to treatment. The study was conducted
with board certified dermatologists in five clinics in
France and five in the United States, in consideration of
the following: VICH GL9 on Good Clinical Practice, 15th
June 2000; Directive 2001/82/EC of the European parlia-
ment, 6th November 2001: The Community Code relat-
ing to veterinary medicinal products; EMEA/CVMP/
816/00, guideline to the statistical principles for veterin-
ary clinical trials – 5th June 2002. Permits to conduct
this study were not required in either country, since this
was a study conducted with authorized products within
current product labeling. Owner consent was obtained
prior to screening any dog for the study.
Animals
Client-owned dogs (≥6 months of age) showing clinical
signs of atopic dermatitis and an owner assessed pruritus
visual analogue scale (VAS) score of at least 50% were
included in the study. All dogs had received adequate
flea treatment as determined by the investigators for at
least four weeks prior to inclusion in the study, had
completed an elimination diet trial, had no active bacter-
ial or fungal infection, and fulfilled at least five of
Favrot’s 2010 criteria [12], confirming the diagnosis of
atopic dermatitis. Dogs were otherwise considered to be
in good health, as determined by a comprehensive phys-
ical examination and clinical pathology (hematology,
clinical chemistry, urinalysis). Any concomitant treat-
ment which could interfere with the assessment of effi-
cacy or safety at any time prior to or during the study
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home environment, received an adequate flea treatment
throughout the study and were managed in their usual
way, without any changes in diet during the study.
Treatment administration
At inclusion (day 0), dogs were randomized to one of the
treatment groups following site specific randomization
lists prepared with SAS®, version 9.2 (2008) (SAS® 9.2 Help
and Documentation, Cary, NC, SAS Institute Inc., Copy-
right 2010), which were not separated for sexes, age or
body weight, and was equally balanced for both treatment
groups. Dogs initiated treatment on day 1 with cyclospor-
ine A (Atopica®, Novartis Animal Health Inc., Basel,
Switzerland) at approximately 5 mg/kg orally once daily
for 28 (±2) days either alone (treatment group 1; n = 25)
or concomitantly (treatment group 2; n = 23) with
prednisolone (Megasolone®, Merial (France); Prednisolone®,
Vedco (USA)) at approximately 1 mg/kg orally once daily
for seven doses (day 1 through 7), followed by approxi-
mately 1 mg/kg orally every other day for a further seven
doses (day 8 through 20). The treatment schedule is sum-
marized in Figure 1. Owners kept a record of treatment ad-
ministration; all drugs dispensed to and returned from the
owner were accounted for at the end of the study.
Observations
Dogs were evaluated by both the owner and the investi-
gator in the clinic on the day of enrollment (clinic visit
1, day 0), after 2 weeks (clinic visit 2, day 14 ± 1) and
after 4 weeks (clinic visit 3, day 28 ± 2) of treatment.Table 1 Prohibited concomitant medications
Treatments prohibited within 7 days of starting the study
● Any antibiotic ● Topical corticosteroids
● Drugs interfering with CsA such as ketoconazole, itraconazole,
miconazole, phenobarbital.
Treatments prohibited within 14 days of starting the study
● Cylosporine A ● Systemic short acting glucocorticosteroids,
including ophthalmic and otic preparations
● Antihistamines ● Non-steroidal anti-inflammatory drugs (NSAIDs)
● Topical calcineurin
inhibitors
● Shampoos (except where the same treatment
regimen is maintained throughout the study).
● Vaccination ● Clomipramine, amitriptyline and fluoxetine and
any other serotonin reuptake inhibitor
Other prohibited treatments
● Allergen specific immunotherapy (except if initiated for at least
9 months and where the same treatment regimen is maintained
throughout the study).
● Treatment with systemic long-acting corticosteroids within the last
3 months
● Essential fatty acids except those used before study initiation for at
least 57 days and where the same treatment regime is maintained
throughout the studyOwner evaluation included an assessment of pruritus with
a visual analogue scale (VAS, [13]) and overall response at
day 14 ± 1 and day 28 ± 2 (Table 2). In addition, on three
separate occasions during each 2 week period be-
tween the scheduled clinic visits, the owner assessed
pruritus and the overall response of the dog in its
own environment. Throughout the study, the owner
documented and reported all adverse events (AEs) to
the investigator.
Clinical evaluation by the investigator at each clinic
visit included: general physical examination, including
body weight, CADESI-03 lesion scoring according to
Olivry et al. [13], overall clinical response and assess-
ment of AEs (Table 2).
Any observation in a treated dog that was unfavorable
and unintended and occurred after treatment adminis-
tration, was considered an adverse event whether or not
considered to be product related, according to the VICH
Guideline 9 [14]. All AEs were described in detail by the
investigator and reported to the relevant regulatory
authorities in accordance with local regulations.
Blood and urine samples were collected within 14 days
prior to inclusion (pre-inclusion screening visit) and on visit
3 (study completion, day 28 ± 2). Complete hematological,
clinical chemistry and urinalysis panels were determined.
Statistical analysis
All statistical analyses were performed with the com-
mercial software package SAS®, Version 9.2 (2008). The
experimental unit was the individual dog, and unless
otherwise indicated, the level of significance for all
two-sided tests performed was α=0.05. The SAS® pro-
cedure npar1way was used to perform the Mann–
Whitney U tests and procedure univariate was applied
in order to calculate summary statistics, for test of nor-
mality (Shapiro-Wilk test) and Wilcoxon paired sample
tests. SAS® procedure mixed was applied to perform ana-
lyses of variance. SAS® procedure freq was applied to cal-
culate contingency tables and to perform Fisher’s Exact
tests. Summary statistics (arithmetic mean, minimum,
maximum, median and standard deviation) were provided
for all continuous parameters of interest.
Efficacy analysis
For the assessment of pruritus, non-parametric Mann–
Whitney tests were applied for the comparisons of
groups at various assessment time points and the per-
centage change in pruritus relative to untreated levels
was calculated. Bonferroni corrections were applied for
the adjustment of the effect of multiple testing. Overall
clinical responses assessed by the investigators were
compared with a Fisher’s exact test. For each group
CADESI-03 lesion scores changes from baseline were
compared with the Wilcoxon test, including Bonferroni
820 714







Figure 1 Study design. Dogs were included in the study on day 0 and received one daily treatment with cyclosporine A (Atopica®, 5 mg/kg)
from day 1 to day 28. In addition dogs in the cyclosporine A and prednisolone group received 1 mg/kg prednisolone once daily, on the
indicated days (arrows). Grey boxes represent clinic visit windows (day 14 ± 1 and day 28 ± 2) and stars represent owner assessment time points.
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covariance (RMANCOVA) was employed for evaluating
the time by treatment interaction on CADESI-03 scores
(normal distribution assumptions for CADESI-03 scores
were partly satisfied after square root transformation).
For normalization of the sum of CADESI-03 scores
across groups, the arithmetic mean for each group at
day 0 was considered as 100% and scores at each time-
point were normalized by multiplying the individual
score by 100 and dividing by the treatment group arith-
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1: mild; 2, 3The level of significance for all parameters was 0.05,
except for pruritus assessed by the owner (primary effi-
cacy end-point). For this endpoint an unplanned interim
analysis was performed and, therefore, the significance
level was adjusted to 0.025 to maintain experiment wise
type 1 error rate.
Safety analysis
Adverse events and associated clinical signs were
summarised and compared between treatment groups.
Mann–Whitney tests were applied for the variousg is not itchy: no scratching, chewing, rubbing or licking observed”
og is extremely itchy: scratching, chewing, rubbing or licking constantly”
ruritus observations on VAS at any time were expressed as a percentage:
%× VAS length / total length of scale [13]
dog’s dermatological condition has deteriorated or not changed
to before treatment.
e: My dog’s dermatological condition has only slightly improved
to before treatment.
y dog’s dermatological condition has clearly improved compared to
tment.
: My dog’s dermatological condition has completely recovered as
to before treatment.
rsening or no change of the clinical signs of the atopic dermatitis as
to initial examination.
e: slight amelioration of the clinical signs of the atopic dermatitis as
to initial examination.
ear amelioration of the clinical signs of the atopic dermatitis as
to initial examination.
: Clinical signs of the atopic dermatitis observed during the first
n have completely disappeareds.
of validated template grading erythema, lichenification, excoriations,
d the sum score for all four lesions at 62 body sites (grades, none: 0;
: moderate; 4, 5: severe) [13].
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tests were additionally applied to test for changes of
clinical pathology parameters from baseline separately
within each group. Comparisons of groups with re-
spect to ‘at least one adverse event’ versus ‘no adverse
event’ were performed with Fisher’s Exact tests.Results
Study population
Forty-eight dogs (24 males and 24 females) of 1.25 –
12.4 years of age were enrolled in France (n = 23) and in
the United States (n = 25). The study population consisted
of 41 pure breed dogs representing 22 breeds, plus 7
mixed breed dogs. The population was evenly distributed
between groups, with no significant differences for any
demographic variables except for mean body weight: dogs
randomized to receive cyclosporine A alone had a signifi-
cantly lower pre-treatment body weight than those ran-
domized to concurrent therapy (16.93 kg vs. 28.66 kg,
respectively: p = 0.0012); this difference remained un-
changed throughout the study.
Four cases received repeated incorrect doses and were
therefore excluded from the efficacy analysis (one dog
was under-dosed with cyclosporine A for the first 12 days
of the study, 2 dogs were under-dosed with cyclosporine
A throughout the study, and 1 dog received prednisol-
one daily instead of every other day during the second
week of treatment). All 48 cases were included in the clin-


























Figure 2 Reduction of pruritus. Mean percentage reduction in pruritus a
with cyclosporine A and prednisolone (○). Bars indicate 95% confidence in
were statistically significant with the exception of day 28 ± 2 (*). Pruritus as
than baseline for both treatment groups, with the exception of day 3 for thconcurrent treatment group n = 23). There were no with-
drawals due to lack of efficacy or adverse events.
Pruritus
For both treatment groups, owners reported a reduction
in pruritus during treatment (Figure 2). By day 14 ± 1,
dogs treated with cyclosporine alone showed 24.6% re-
duction, while dogs with concurrent treatment with
prednisolone had an average pruritus reduction of 72.8%
(Table 3). Differences in pruritus reduction between
groups were significant for all time-points recorded with
the exception of the final assessment (day 28 ± 2), in
which pruritus reduction in dogs treated with cyclospor-
ine alone was 42.4% compared with 65.1% in dogs with
concurrent treatment (not significant, p >0.025).
When comparing to baseline, non-parametric pair-wise
analysis of pruritus showed a significant reduction in VAS
as assessed by the owner as early as day 3–4 in dogs
treated with cyclosporine A and prednisolone (p = 0.0001),
while in dogs treated with cyclosporine A alone, a signifi-
cant improvement of pruritus could be observed from day
7–8 onwards (p = 0.0022). VAS pruritus scores at all other
time points remained significantly lower than baseline for
both treatment groups.
Overall response
Overall response assessments followed a similar trend as
pruritus. Fifty percent of the dogs that received cyclospor-
ine A with prednisolone had either a good or an excellent






s assessed by the owner for dogs treated with cyclosporine A (▲) or
terval. At every time point after day 0 differences between both groups
sessment by the owner at every time point was significantly lower
e cyclosporine group (1, p = 0.3583).
Table 3 Owner-reported pruritus VAS scores and reduction from baseline following treatment
Day Treatment (n = 22) Score Score change from baseline (%) p-value
Mean2 Median s.d. Min Max Mean (95% CI)
0 Cyclosporine A 79.28 80.58 12.45 52.60 98.92 - -
Cyclosporine A and prednisolone 73.90 73.12 11.83 50.75 100.00 -
3-4 Cyclosporine A 77.43 79.03 11.42 48.50 95.02 −1.18 (−7.8,5.5) 0.0008
Cyclosporine A and prednisolone 47.65 50.00 22.86 10.95 96.79 −36.33 (−48.7,-24.0)
7-8 Cyclosporine A 67.79 69.65 14.62 38.71 95.02 −13.04 (−22.3,-3.8) 0.0008
Cyclosporine A and prednisolone 29.21 29.50 20.46 1.99 72.04 −60.61 (−73.3,-47.9)
10-11 Cyclosporine A 65.81 67.99 13.47 36.56 87.06 −15.31 (−24.2,-6.5) 0.0008
Cyclosporine A and prednisolone1 23.08 16.13 22.97 0.00 74.63 −68.73 (−82.7,-54.7)
14 ± 1 Cyclosporine A 58.69 57.53 18.03 26.87 93.03 −24.57 (−34.9,-14.2) 0.0008
Cyclosporine A and prednisolone 20.37 12.90 20.22 0.00 75.62 −72.79 (−84.4,-61.1)
17-18 Cyclosporine A 50.45 47.54 19.71 20.40 88.56 −34.62 (−47.0,-22.3) 0.0008
Cyclosporine A and prednisolone 19.33 10.75 19.50 0.00 70.00 −73.57 (−84.9,-62.3)
21-22 Cyclosporine A 48.33 47.79 20.26 16.13 88.56 −37.00 (−50.1,-23.9) 0.0128
Cyclosporine A and prednisolone 21.23 11.29 24.84 0.00 84.58 −70.55 (−85.5,-55.6)
24-25 Cyclosporine A 43.69 42.36 24.29 3.23 88.56 −42.41 (−58.2,-26.6) 0.0240
Cyclosporine A and prednisolone 19.90 10.75 24.42 0.00 93.03 −73.10 (−86.9,-59.3)
28 ± 2 Cyclosporine A1 43.44 43.01 25.09 3.23 89.05 −42.36 (−58.2,-26.5) 0.2160
Cyclosporine A and prednisolone 26.26 15.05 28.54 0.00 94.03 −65.12 (−81.1,-9.1)
1n = 21; 2arithmetic mean; s.d. standard deviation.
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from day 7–8 onwards. In contrast, about 50% of the dogs
treated with cyclosporine A alone had a moderate response
on day 3–4. Response to this treatment improved there-
after, and by day 21–22 approximately 70% of the dogs in
this treatment group had a good or excellent response.
For all assessments up to day 20–21 owners reported a























3-4            7-8           10-11        14±1  17-1
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Figure 3 Owner overall assessment of clinical response. Percentage of
with cyclosporine A (C) or cyclosporine A and prednisolone (CP) as assesse
Exact, two-tailed).in comparison to cyclosporine A alone. For the last 2 as-
sessments (day 24–25 and day 28 ± 2) the overall response
was not significantly different between the groups. Signifi-
cance values at all assessment points by the owners are
summarized in Additional file 1: Table S1.
Investigators’ evaluations also indicated the overall
clinical response to be significantly better for the con-
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*
poor, moderate, good and excellent responders among dogs treated
d by the owner at the different observation dates. *: p≤ 0.05 (Fisher's
Table 4 Overall clinical response: number (and
percentage) of poor, moderate, good and excellent
responders as assessed by the investigator






14 ± 1 Poor 4 (18.2) 1 (4.5) 0.0330
Moderate 9 (40.9) 5 (22.7)
Good 8 (36.4) 8 (36.4)
Excellent 1 (4.5) 8 36.4)
28 ± 2 Poor 4 (20) 2 (9.1) 0.4655
Moderate 3 (15) 2 (9.1)
Good 11 (55) 12 (54.5)
Excellent 2 (10) 6 (27.3)
























Figure 4 Investigator assessment of skin lesions. Sum of CADESI-
03 scores, normalized. Mean and 95% confidence interval are
presented for each evaluation day). *: p≤ 0.05 at day 14 ± 1 and
28 ± 2 for both treatment groups against baseline (Wilcoxon paired
sample test).
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were no longer significant (p = 0.4655).
CADESI-03 scores
At both post treatment clinic visits, CADESI-03 scores
for erythema, lichenification, excoriations, alopecia and
the sum of all scores were significantly lower thanTable 5 CADESI-03 scores for the 4 lesions evaluated and
sum of all scores by day of evaluation and treatment
group








Erythema 0 43.27 (29.8) 49.36 (26.81) 0.1185
14 ± 1 27.14 (22.61) 20.36 (21.97)
28 ± 2 23.62 (33.17) 19.95 (19.47)
Lichenification 0 17.23 (18.29) 23.23 (21.8) 0.6708
14 ± 1 8.41 (9.03) 8.18 (11.17)
28 ± 2 6.86 (8.03) 9.55 (16.49)
Excoriations 0 12.82 (15.53) 16.95 (17.61) 0.2552
14 ± 1 4.36 (5.92) 4.05 (8.85)
28 ± 2 3.71 (5.44) 7.27 (16.67)
Alopecia 0 20.00 (28.46) 20.32 (15.33) 0.1590
14 ± 1 13.14 (14.27) 7.95 (10.17)
28 ± 2 6.38 (6.79) 9.45 (15.30)
Sum of scores 0 93.32 (64.75) 109.86 (67.39) 0.0750
14 ± 1 53.05 (37.39) 40.55 (43.59)
28 ± 2 40.57 (46.61) 46.23 (63.24)
*RMANCOVA analysis for the interaction of the variables treatment group and
length of treatment.
1n = 21 for this treatment on day 28 ± 2.pre-treatment values, for both treatment groups (Table 5
and Figure 4).
A repeated measures model of covariance (RMANCOVA)
analysis suggested a weak interaction between treatment
and time, although this did not reach the significance level
(p = 0.0750, Table 5). P-values for the effect of main factors
(time, treatment) are not significant.
Adverse events
A total of 56 AEs (cyclosporine A alone = 34; concurrent
therapy = 22) were reported from 33 dogs. Approxi-
mately 76% of cases treated with cyclosporine A alone
(n = 19/25) and 61% of cases treated with concurrent
prednisolone (n = 14/23) showed at least one AE (differ-
ence not significant, p = 0.3532). No dogs died, were eu-
thanized or stopped treatment due to AEs. None of the AEs
reported was considered life-threatening, resulted in per-
manent disability or incapacity. All dogs made a complete
recovery, except for five dogs (n = 3, cyclosporine A alone:
conjunctivitis, luxating patella (both unlikely related to treat-
ment) and otitis externa (unclassifiable); n = 2, concurrent
therapy: abnormal laboratory value (unlikely related to
treatment) and scaling, possibly related to treatment).
Table 6 lists clinical signs reported by treatment and orga-
nized by a customized veterinary dictionary for drug re-
lated activities.
The most commonly reported clinical signs in the
cyclosporine A alone group were associated with the di-
gestive tract (47% of all reported clinical signs). A signifi-
cantly lower incidence of vomiting was reported for the
concurrent therapy group (2 reports in 2 dogs, vs. 13 re-
ports in 10 dogs in the cyclosporine A alone group).
Vomiting episodes were mild and typically only lasted
Table 6 Clinical signs reported and number of dogs
affected per treatment group
Clinical sign* Cyclosporine





Digestive tract disorders 20 (14) 12 (8) 0.1810
Abdominal pain 1 0 0.3589
Digestive tract hypermotility 0 1 0.3169
Flatulence 1 1 0.9762
Diarrhea 5 (5) 7 (6) 0.5815
Stomatitis 0 1 0.3169
Vomiting 13 (10) 2 (2) 0.0116
Renal and urinary disorders 4 (3) 7 (5) 0.3726
Cystitis 0 2 (2) 0.1441
Polyuria 1 2 (2) 0.5223
Uremia 0 1 0.3169
Urinary incontinence 1 0 0.3589
Urine abnormalities 2 (2) 2 (2) 0.9485
Skin and appendages disorders 10 (8) 3 (3) 0.1080
Bacterial skin infection 1 1 0.9762
Dermatitis 0 1 0.3169
Erosion 0 1 0.3169
Fungal skin infection 1 0 0.3589
Papilloma 1 0 0.3589
Pruritus 1 0 0.3589
Pyoderma 6 0 0.0264
Systemic disorders 2 (2) 13 (8) 0.0190
Abnormal test result 1 3 (3) 0.2717
Anorexia 0 1 0.3169
Lethargy 0 4 (4) 0.0329
Polydipsia 1 4 (4) 0.1384
Pyrexia 0 1 0.3169
Others
Hyperactivity 1 0 0.3589
Tachypnea 1 1 0.9762
Musculoskeletal disorder 1 0 0.3589
Acid–base disorder 0 1 0.3169
Conjunctivitis 2 (2) 1 0.6226
Otitis externa 2 (2) 0 0.1798
*Several AEs had more than one clinical sign; total number of clinical signs
reported: 81.
1The numbers in parentheses indicate the number of dogs showing the
corresponding clinical sign. Dogs may have had more than one AE.
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required in any case. There was no significant differ-
ences between the groups in the incidence of skin and
appendage disorders, with the exception of pyoderma,
which was more frequently reported in the cyclosporine
A alone group.In contrast, systemic disorders were reported more
frequently in the concurrent therapy group, in particular
lethargy which was only observed in the concurrent
therapy group (4 reports, p = 0.033). The reports of leth-
argy were of mild to moderate severity, started within
the 20 days of the study (i.e. during the administration
of prednisolone) and they resolved within 3 to 8 days
following the end of prednisolone administration. Four
reports of polydipsia in the combined treatment group
were recorded, while only one polydipsia report oc-
curred in the cyclosporine A group (p = 0.1384). Two
dogs were reported with abnormal laboratory values in
the cyclosporine A and prednisolone group consistent
with the administration of prednisolone (elevated alka-
line phosphatase; elevation of alkaline phosphatase, AST
and ALT), while a third dog had elevated amylase, lipase,
and cholesterol, in addition to pre-existing elevated cre-
atinine and BUN values (indicating progression of a pre-
existing condition). In the cyclosporine A group, one
dog had a marginal BUN elevation, which recovered
without intervention and was considered unlikely to be
related to treatment.
Hematology and clinical chemistry
No significant differences in mean baseline haematological
or clinical chemistry values between the groups were
observed at inclusion. Within each treatment group some
differences were observed at the final assessment. A statis-
tically significant increase in hematocrit and in the per-
centage of lymphocytes (in relation to total leukocytes)
was observed in dogs treated with cyclosporine A alone
Similarly, clinical chemistry values at study end revealed a
statistically significant increase in cholesterol and a de-
crease in in ALT and AST in the cyclosporine A group, as
well as an increase in albumin in the cyclosporine A and
prednisolone group. An elevation in glucose was observed
in both groups. However, all mean values for haematology
and clinical chemistry were within reference range and the
changes were considered clinically not significant. A sum-
mary of hematological and clinical chemistry changes is
presented in Additional file 1: Table S2. There were no
significant differences in any of the urine parameters
measured.
Discussion
Administration of cyclosporine has been shown to be ef-
fective and safe in the treatment of atopic dermatitis (re-
cently reviewed by Palmeiro [15]). Here, we confirm that
cyclosporine administered at 5 mg/kg once daily for
28 days administered concurrently with prednisolone ad-
ministered for the first 20 days (1 mg/kg once daily for
one week followed by 1 mg/kg once every other day for a
further seven doses) was safe and resulted in a rapid re-
duction of pruritus in dogs treated for atopic dermatitis.
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study. Since owners consider pruritus the greatest bur-
den to their dog’s quality of life [3], periodic evaluations
of pruritus were primarily conducted by the owners, but
also by the investigators. Owners reported a significant
reduction of pruritus as early as 3–4 days after the initi-
ation of treatment in dogs that received prednisolone
concomitantly with cyclosporine A, and after 7–8 days
in dogs treated with cyclosporine A alone. The sharper
reduction in owner-reported pruritus in dogs in the con-
comitant treatment group (average reduction on day 7–
8 of 60%) was in agreement with the overall assessment
of clinical response. After 4 weeks of treatment, how-
ever, pruritus reduction was comparable between groups
and similar to that reported elsewhere [6,16]. Further-
more, a similar proportion of dogs had either a ‘good’ or
‘excellent’ overall response to therapy on the final visit.
The CADESI-03 scoring system used here has been
validated as a tool to assess change in skin lesions associ-
ated with atopic dermatitis [13]. In both treatment groups,
CADESI-03 lesion scores were significantly lower both at
day 14 ± 1 and 28 ± 2 when compared to pre-treatment
scores, and there were no differences in lesion scores be-
tween groups at either visit. However, since the dispersion
of the CADESI-03 scores for both treatments at each time
point was considerable, it is possible that a larger data set
would have allowed confirmation of a significant differ-
ence of CADESI-03 scores between groups at day 14 ± 1.
Lesion scores after four weeks were remarkably similar, in-
dicating that any potential difference between groups in
CADESI-03 scores would be temporary (e.g. around
day 14). Altogether this data shows that even though
cyclosporine A administration leads to an improvement in
atopic dermatitis signs 4 weeks after the initiation of ther-
apy irrespective of the concurrent administration of ste-
roids, dogs which had the benefit of an initial course of
prednisolone had an accelerated reduction of pruritus and
improvement of clinical score.
None of the AEs observed in this study were consid-
ered life-threatening, nor did they result in permanent
disability or incapacity. The most commonly reported AEs
following treatment with cyclosporine A were vomiting
(25% overall prevalence) and diarrhea (15% overall preva-
lence) [6]. In this study, 10 out of 25 (40%) of the dogs in-
cluded in the clinical safety analysis in the cyclosporine A
group reported 13 vomiting events, in line with previous re-
ports [5]. The reported vomiting was mild and improved
spontaneously within a few days with continued use. In con-
trast, the prevalence of vomiting in the concurrent treat-
ment group was significantly lower (9%). This observation
was unexpected, and it is unclear why concurrent prednisol-
one would have reduced vomiting in dogs being treated with
cyclosporine A. However, in view of the limited number of
dogs included in this study, this observation may beincidental and should be interpreted with care. Additional
studies may be warranted to investigate this potential effect.
The incidence of pyoderma in dogs treated with cyclo-
sporine A alone was significantly higher than that in dogs
treated with cyclosporine A and prednisolone. Pyoderma
and otitis externa are often associated with atopic derma-
titis and the observed incidence in this study may have
been a result of the prohibition of the use of concurrent
medications, notably antibiotics and otic preparations,
usually used to manage these signs. Bacterial pyoderma is
usually secondary to trauma. The dermal abrasion caused
by scratching enables bacteria to colonize the skin and es-
tablish an infection. The data presented here suggests that
the concomitant administration of prednisolone with cyclo-
sporine A significantly reduces pruritus early in the course
of treatment; therefore it is possible that dogs treated with
cyclosporine A and prednisolone developed less secondary
pyoderma due to the rapid reduction in pruritus and subse-
quent reduction of self-induced traumatic pyoderma.
Several studies have shown that treatment with elevated
doses of glucocorticoids during prolonged periods of time
can lead to immunosuppression [9]. For example, admin-
istration of 2.2-6.6 mg/kg of prednisolone twice daily for
induction, followed by 1.1 to 2.2 mg/kg for maintenance
to dogs can result in immunosuppressive effects, and in-
creased risk of infection and poor wound healing are, in
fact, among the most common side effects of glucocortic-
oid treatment in dogs [17]. In this study, a moderate dose
of prednisolone was administered during a limited period
and probably too short to result in a higher incidence of
corticosteroid-related pyoderma.
The most frequently observed adverse events in the
concurrent treatment group were polyuria, polydipsia
and lethargy. These observations are consistent with re-
ports of lethargy in dogs and cats being treated with glu-
cocorticoids [17]. Polydipsia with secondary polyuria is a
relatively common finding in dogs treated with glucocor-
ticoids, and therefore this trend was expected [8]. All
cases of polyuria and/or polydipsia and/or lethargy
reported in dogs that had received cyclosporine A and
prednisolone had resolved on, or before the final visit.
Increases in liver enzymes, are also known side effects
associated with the administration of corticosteroids
[17]. In this study, three dogs were reported with en-
zyme elevations consistent with prednisolone therapy,
two of which were transitory and clinically not signifi-
cant, and a third case in which the abnormal values were
likely to be related to a pre-existing condition. No fur-
ther clinically significant changes in hematological, clin-
ical chemistry or urinalysis parameters were observed.
Conclusion
In conclusion, the data presented shows that the concur-
rent administration of a short course of prednisolone, at
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atopic dermatitis is well tolerated and efficacious in rap-
idly reducing pruritus. The combined treatment improves
the dog’s overall clinical response assessed by the owner
as soon as 3 to 4 days post treatment initiation. The ad-
verse events observed were consistent with those expected
for the individual veterinary medicinal products.
Additional file
Additional file 1: Overall clinical response assessed by the owner
and summary of hematological and clinical chemistry changes per
treatment group.
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